Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

apogepha arzneimittel gmbh - propiverin - obložena tableta - propiverin 13,64 mg / 1 tableta - propiverin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

apogepha arzneimittel gmbh - propiverin - kapsula s prirejenim sproščanjem, trda - propiverin 40,92 mg / 1 kapsula - propiverin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

apogepha arzneimittel gmbh - propiverin - kapsula s prirejenim sproščanjem, trda - propiverin 40,92 mg / 1 kapsula - propiverin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

apogepha arzneimittel gmbh - propiverin - kapsula s prirejenim sproščanjem, trda - propiverin 27,28 mg / 1 kapsula - propiverin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

apogepha arzneimittel gmbh - propiverin - kapsula s prirejenim sproščanjem, trda - propiverin 27,28 mg / 1 kapsula - propiverin

Evropska unija - slovenščina - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bial portela & companhia s.a. - opikapon - parkinsonova bolezen - anti-parkinsonska zdravila - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

virbac 1ère avenue -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz gmbh - azitromicin - filmsko obložena tableta - azitromicin 250 mg / 1 tableta - azitromicin